Xencor
Open
$11.93
Prev. Close
$11.93
High
$11.95
Low
$11.90
Market Snapshot
$829.79M
-9.0
-3.59
$110.49M
260
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
emptyResult
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Recently from Cashu
Xencor Revises Revenue Outlook for Ultomiris Royalties Amid Shifting Market Conditions
Xencor Adjusts Revenue Outlook for Ultomiris Royalties Amid Market Changes In a recent announcement, Xencor Inc. recognizes the necessity to revise its revenue outlook specifically related to royaltie…
Xencor Revises Revenue Outlook for Ultomiris Amid Changing Market Dynamics
Xencor Takes Strategic Steps to Reassess Revenue Projections for Ultomiris Xencor Inc. announces a revision of its revenue outlook regarding royalties from Ultomiris, a drug that plays a significant r…
Xencor Revises Revenue Outlook for Ultomiris Royalties Amid Market Changes
Xencor Adjusts Revenue Outlook for Ultomiris Royalties Xencor Inc. has announced a revision to its revenue outlook concerning royalties from Ultomiris, a key product in its pharmaceutical portfolio. T…
Xencor's Innovations in Cancer Immunotherapy: Advancements and Trials in Targeted Therapies
Innovative Approaches in Cancer Immunotherapy: GT Biopharma's Progress GT Biopharma, Inc., a clinical-stage biotechnology company based in San Francisco, is making notable strides in the field of immu…